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Abstract
As the coronavirus disease 2019 (COVID-19) pandemic continues to generate significant morbidity and mortality as well 
as economic and societal impacts, the landscape of potential treatments has slowly begun to broaden. In the case of a novel 
disease with widespread consequences, society is more likely to place significant value on interventions that reduce the 
outsized economic burden of COVID-19. Treatments for severe disease will have a different value profile to that of large-
scale vaccines because of their application in targeted and potentially small subsets of those with symptomatic disease vs 
broad deployment as a preventative measure. Where vaccines reduce transmissibility of COVID-19, use of therapeutics will 
target symptoms, up to and including death for infected individuals. This paper describes discussions from a virtual expert 
panel that met to attempt a consensus on how existing principles of economic evaluation should be applied to therapeutics 
that emerge in a pandemic setting, with specific focus on severe hospitalised cases of COVID-19. The panel concluded that 
the core principles of economic evaluation do not need to be drastically overhauled to meet the challenges of a pandemic, 
but that there are several additional elements of value such as equity, disease severity, insurance value, and scientific and 
family spillover effects that should be considered when presenting results to decision makers. The panel also highlighted 
the persistent challenges on how society should value novel therapies, such as the appropriate cost-effectiveness threshold 
to apply, which are particularly salient during a pandemic.
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Key Points for Decision Makers 
Although usual economic evaluation principles remain 
unchanged within the context of the coronavirus disease 
2019 pandemic, treatment evaluation should consider 
the broader benefits of restoring economic and social 
activity.
Several additional elements of value should be consid-
ered, including the disproportionate impact on certain 
patient groups, long-term effects of the disease, insur-
ance value and impact on families, and the evaluation 
should adapt as the relative importance of these elements 
change as the pandemic evolves.
Finally, careful consideration should be given to the most 
appropriate cost-effectiveness threshold to apply in a 
pandemic setting.
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1 Introduction
The coronavirus disease 2019 (COVID-19) pandemic has, 
as of July 2021, infected over 180 million individuals and 
caused almost four million deaths worldwide, with over 30 
million cases in the USA and India, with 600,000 deaths 
in the USA and 400,000 in India [1]. Alongside significant 
health impacts, countries around the world have endured 
heavy and wide socioeconomic consequences of the virus—
in the USA alone, the economic toll of COVID-19 is esti-
mated at over $16 trillion, which is considered a conserva-
tive estimate [2].
The majority of patients with COVID-19 have no or 
mild symptoms and recover from the disease. Up to 22% of 
patients experience severe infection and require hospitalisa-
tion [3]. These patients may experience severe consequences 
such as acute respiratory distress syndrome, necessitating 
intubation/mechanical ventilation or extracorporeal mem-
brane oxygenation in intensive care units, and COVID-19, 
sometimes independent of an intensive care unit stay, can 
lead to long-lasting symptoms post-discharge. Through 
improvements in clinical management, mortality rates have 
dropped since the start of the pandemic; however, 8–20% 
of patients hospitalised with COVID-19 in the USA still 
die [4, 5]. Mortality rates adjusted for population size have 
been particularly high in South American countries such as 
Brazil, Peru and Argentina, as well as European countries 
such as the UK and Italy [6]. Patients at increased risk of 
severe COVID-19 include those of an older age and/or with 
underlying medical conditions including obesity [7].
A key issue from a health economics perspective 
is whether and in what situations standard utilitarian 
approaches and frameworks in a conventional cost-effec-
tiveness analysis—incremental benefits as measured by 
quality-adjusted life-years (QALYs)—should be expanded 
to incorporate other elements of value that are specifically 
relevant to a pandemic situation. These may include addi-
tional value based on impact to non-health sectors, equity 
impact, or interventions that are life saving or drastically 
improve lives in the face of imminent death. Methods cur-
rently exist to incorporate these impacts by, for example, 
weighting of QALYs [8, 9]. There is, however, no indication 
that these methods should be specifically invoked in times 
of a pandemic. Indeed, if cost-effectiveness frameworks are 
modified for pandemics, results cannot be directly compared 
to pre-pandemic therapies. None of the issues raised below 
is exclusively relevant for a pandemic, but some issues were 
brought into sharp relief during the COVID-19 pandemic. In 
addition to the methodological considerations pertinent to 
economic evaluations during a pandemic, how we interpret 
the results and assign appropriate value to interventions dur-
ing a pandemic is another key issue.
1.1  Therapeutics for COVID‑19 in the Context 
of Vaccines
There are 20 COVID-19 vaccines that have gained regula-
tory approval in at least one country as of July 2021 [10], 
and government-sponsored vaccination campaigns are now 
underway. Uncertainty surrounding the rate of uptake, a full 
picture of the vaccine safety profile, and the length of con-
ferred immunity and effectiveness against emerging variant 
strains of the virus in real-world settings are still to be clari-
fied. While vaccines will reduce population-level infection 
spread, any of these factors may mean a continued reliance 
on therapeutics to reduce mortality, symptom severity, dura-
tion, or complications among infected patients. We there-
fore limit the scope of this paper to the therapeutics class in 
patients with COVID-19 requiring treatment, where decision 
problems around resource allocation are more likely to arise. 
We define the therapeutics class as any active treatment for 
symptomatic infection. Discussions on this topic took place 
in a 1-week virtually convened panel in October 2020, using 
an interactive platform that allowed the six authors to answer 
questions and post replies directly to each other.
Over 460 trials of COVID-19 therapeutics have been 
evaluated by the US Food and Drug Administration with 
11 Emergency Use Authorizations being issued [11]. Three 
Emergency Use Authorizations cover therapy options for 
patients requiring hospitalisation, two of which include 
remdesivir [12–14]. Another Food and Drug Administra-
tion-approved drug, dexamethasone, was repurposed for 
patients with COVID-19 on supplemental oxygen or those 
who are intubated [15]. The Institute for Clinical and Eco-
nomic Review’s assessment of remdesivir monotherapy 
[16] was met with praise for its rapidity and transparency, 
but also with some criticism over its lack of consideration 
of non-health effects and a societal perspective, lack of an 
open-source model, as well as the use of a more stringent 
cost-effectiveness threshold than the organisation typically 
considers [17, 18]. The remdesivir evaluation underscores 
debates at the heart of valuing therapeutics during the 
COVID-19 pandemic: compared with vaccines, there is less 
clarity on the degree of impact for therapeutics on broader 
social and economic consequences of the pandemic. There 
was also consideration of the appropriate willingness-to-pay 
threshold to be used, in the face of potentially a large number 
of patients requiring therapy. As financing for therapeutics 
research and development is concentrated in the USA, this 
paper uses the US healthcare system for most examples. 
However, the larger context of pandemic-based value assess-
ment may be applied globally keeping in mind that countries 
will generally vary in their assessment given differences in 
epidemiology, healthcare delivery and economic conditions. 
This paper starts with a presentation of different elements of 
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value currently identified in existing frameworks and how 
they relate to economic evaluations for pandemic interven-
tions, followed by a discussion on how these considerations 
impact on a willingness-to-pay threshold for value assess-
ments and price setting.
2  Existing Value Frameworks and Elements 
Relevant to a Pandemic
The existing value frameworks [9, 19, 20] and methods are, 
by and large, generalisable—with rewards driven by health 
gain and medical cost offsets—but some different empha-
ses are warranted as a result of a pandemic, with specific 
implications for including or excluding them from a value 
assessment. Alternative or additional elements of value 
have been discussed in a number of different forums, with 
the International Society for Pharmacoeconomics and Out-
comes Research Special Task Force on Value Assessment 
Frameworks’ “value flower” [9] having summarised many 
elements not incorporated in traditional value assessments. 
In the following sections, we discuss a selection of value 
elements of particular importance to novel therapeutics in 
the pandemic context.
2.1  Equity
COVID-19 disproportionately affects racial and ethnic 
minorities and low-income patients in terms of case rates, 
severity of disease and mortality [21, 22]. Existing inequali-
ties in the US healthcare system persist in the face of a pan-
demic and may be exacerbated. “Essential workers”, dis-
proportionately low income and minority, are more likely to 
be unable to work from home, more often in service occu-
pations, childcare, factory, farm work, or custodial work, 
and have borne the brunt of infection risk since the spread 
of COVID-19 in the USA [23]. Even in countries with a 
homogenous ethnic population, such as Japan, disparities in 
outcomes were found among those with differing socioeco-
nomic status [24], suggesting that equity considerations will 
have widespread application globally. In low-income and 
middle-income countries (LMICs), equity may need to be 
considered slightly differently. It may not only be accounting 
for differing outcomes among sub-populations, but which 
outcomes are being considered. For example, the emphasis 
on mortality as the most readily available metric may ignore 
the morbidity impact on the younger generations who have 
a lower risk of dying from COVID-19, but who make up a 
larger proportion of the population in LMICs and who may 
form the essential core of the country’s economy [25].
When valuing therapeutics for a pandemic that has a dis-
proportionate impact on particular subsets of the population, 
it is advisable to consider methods that can account for any 
differential impacts. The distributional form of cost-effec-
tiveness analysis (DCEA) evaluates interventions with dif-
ferential impacts on socioeconomic subgroups and compares 
the magnitude in each group [26, 27]. In lieu of a full DCEA, 
which would require trial data or a decision-analytic model 
to empirically inform the distribution of effects, Love-Koh 
et al. describe an aggregate DCEA for health technologies 
that rolls up existing data alongside a measure of inequal-
ity [28]. Use of the DCEA model can help value therapies 
based on reductions in health inequities among specified 
at-risk subgroups. As an alternative, the Generalized Risk-
Adjusted Cost-Effectiveness (GRACE) approach [29] could 
also provide a means of conducting economic evaluations 
that allow incorporation of variables such as severity of ill-
ness for those who experience a disproportionate burden 
of the same disease. Both methods challenge the implicit 
assumption that a gain in health utility is equally valued by 
everyone.
2.2  Severity of Disease
Hospitalised patients with COVID-19 may experience 
complications, including bacterial infections, acute kidney 
injury, respirator-induced lung injury, malnutrition and gen-
eralised weakness [21]. Moreover, patients with COVID-19 
of any severity may experience ongoing fatigue, the inability 
to concentrate and/or other symptoms, collectively dubbed 
post-acute sequelae of SARS-CoV-2 infection [30]. Will-
ingness to pay for therapies may be increased from both 
the patient and societal perspective in reducing potential 
long-term hospitalisation and post-hospitalisation outcomes 
even if average QALY gains across the entire population 
are similar to those for a non-severe condition. In theory, 
therapeutics that prevent severe COVID-19 cases would be 
rewarded for clinical improvement among patients with the 
most burdensome symptoms. Given that only a minority 
of COVID-19 cases require hospitalisation, as well as the 
dearth of long-term clinical data post-discharge to compare 
against other severe conditions, the additional value for ther-
apeutics in preventing severe COVID-19 outcomes remains 
an issue of debate. However, some sub-populations are at 
high risk of severe complications of COVID-19 including 
prolonged hospital stay or death [31], potentially even after 
vaccination, either due to breakthrough infection or waning 
immunity [32, 33]. Adjusting for life expectancy and the 
impact of existing co-morbidities, a recent study has shown 
that the burden of QALYs lost due to such deaths can be 
substantial in many countries [34]; international variation in 
this burden is driven by age distribution at the time of death, 
which implicitly accounts for differing levels of co-morbid-
ities, as well as total number of deaths within each country.
What further confounds these evaluations is the uncer-
tainty of results in current studies. Uncertainty around the 
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long-term impacts of COVID-19 is especially large and to be 
expected; however, evaluations of acute outcomes are also 
subject to uncertainty because of several factors. Trials are 
being designed in a rapid adaptive manner, in a disease area 
that continues to evolve, with therapy guidelines that are 
constantly being updated. These are all leading, at times, to 
contradictory results on acute outcomes. An example of this 
was the extent to which remdesivir could prevent mortality, 
estimates of which initially relied on the ACTT-1 trial [35] 
and were later contradicted by the SOLIDARITY trial [36]. 
This highlights the difficulty of quantifying reductions in 
severity, morbidity and mortality from treatment when evi-
dence is emerging at a rapid pace, as well as the importance 
of conducting thorough sensitivity analyses to account for 
all plausible outcomes.
2.3  Fear of Contagion/Insurance Value
Reducing the “fear of contagion” has been suggested as an 
externality that is often overlooked in economic evaluations 
[9]. Though a single therapeutic may not have a significant 
or oversized effect on fear of contagion reduction, its ben-
efits may be accrued as one component of a complementary 
successful intervention landscape (including vaccines and 
other nonpharmaceutical interventions). The economic con-
sequences of fear of contagion have been called “fearonomic 
effects” and may include business health impact and social 
life losses [37]. According to one study, “fearonomic effects” 
in China totalled $275 billion, or 1.9% of GDP, during the 
Lunar New Year week alone. Ma et al. have published a 
checklist for measuring the economic impact due to fear of 
contagion, quantifying both near and long-term deficits dur-
ing a pandemic [37].
Insurance value places an additional value on the per-
sonal health risk reduction from being infected as well as 
the financial risk protection of insuring the population [9]. 
As with fear of contagion, any single therapeutic is unlikely 
to have significant benefit in illness or financial risk reduc-
tion, but rather, incorporates some share of benefit from the 
landscape of COVID-19 treatment options. In diseases with 
severe or long-term sequelae, as with COVID-19, therapeu-
tics that address and/or add certainty in the reduction of ill-
desired health consequences have an associated value bene-
fit. Lakdawalla et al. describe the methodology for reflecting 
insurance value through consumer utility maximisation in an 
economic value assessment [9]. Consideration of either of 
these value elements is unlikely to have a significant impact 
on economic evaluations of current therapeutics; these ele-
ments would be considered more important when evaluating 
a therapeutic with significant effectiveness, for example, one 
that lowers viral load and therefore leads to decreased trans-
mission along with symptom alleviation, or when evaluating 
the entire therapeutic class as a strategy.
2.4  Scientific and Family Spillover Effects
Scientific spillovers, a type of economic externality, can add 
value to a therapy that creates a significant advancement 
in the scientific knowledge base for a novel or unknown 
disease. Therapies with novel mechanisms of action, or 
therapies that treat previously untreatable diseases, “light 
the path” for additional innovation and can be rewarded to 
encourage additional knowledge production in the therapy 
area [9, 38]. Therapies developed for COVID-19 have the 
potential to provide this spillover effect, or indeed to benefit 
from prior spillovers (e.g. remdesivir and dexamethasone 
were originally developed for other diseases).
The impact of severe disease and its associated therapies 
on family members, particularly those fulfilling an infor-
mal caregiving role, has been well documented, especially 
in neurological diseases such as Alzheimer’s disease and 
Parkinson’s disease [39], though systematic incorporation 
of such an impact into economic evaluations remains low 
[40]. This may be particularly true for LMICs, where data to 
quantify the impact on non-patients are difficult to generate. 
Imposed self-isolation for patients with severe COVID-19 
whether within a home or hospital will undoubtedly affect 
the entire household (i.e. “family spillover” effects), includ-
ing those who must give informal care to the patient from 
a distance. Matters are further complicated by the potential 
economic impact on the family, if the patient is also the 
main source of income. There is some measure of value 
associated with improved treatment outcomes at the family/
household level.
2.5  Incorporation of Additional Perspectives
For the purposes of an economic evaluation, including set-
ting the price of a single therapeutic, the healthcare sec-
tor tends to be the main focus as payers do not generally 
consider non-health effects when underwriting premiums 
or setting reimbursement levels [41]. However, the Second 
Panel on Cost-Effectiveness in Health and Medicine recom-
mended that economic evaluations consider both healthcare 
sector and societal perspectives [9, 42] as the reference case 
for all appraisals. The case for presenting both perspectives 
is especially relevant in a pandemic setting, where the value 
of a vaccine or therapeutic that addresses social, economic 
and health system upheaval necessitates consideration of 
societal benefits relevant to health systems and policymak-
ers. Rewards for improvement in constrained hospital sys-
tem capacity and return to work/school are not appreciated 
by a traditional value assessment [43]. Non-health impacts 
are essential components of a therapeutic’s value assess-
ment from a societal perspective, for example, given signifi-
cant unemployment during COVID-19. The Second Panel 
recommends including productivity effects in added costs 
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in the numerator rather than as a utility adjustment in the 
denominator along with the “Impact Inventory” that lists 
the affected non-health sectors, including lost productivity, 
consumption and social services [19]. However, a lack of 
systematically produced non-health estimates hampers the 
synthesis of evidence from a valuation and price-setting per-
spective. Variation in the methods employed to incorporate 
these non-healthcare perspectives can also be a challenge 
[44], with results that lead to different conclusions. As bet-
ter data become available, estimation of non-health effects 
will improve. The challenge is especially compounded in 
LMICs, where reliance on informal family care is high but 
data to quantify it are low [45]. In the meantime, societal 
and non-societal costs can be included in evaluations to be 
presented as scenario analyses alongside a base case as is 
already permissible in many countries’ pharmacoeconomic 
guidance, such as Spain, Italy and Australia [46–48].
Opportunity costs, however, could be more readily incor-
porated into an economic evaluation of COVID-19 therapies. 
Opportunity costs for COVID-19 vaccines/therapeutics vs 
other interventions can be explicitly measured to support 
decisions from a public health and healthcare system capac-
ity perspective. Burdens on the healthcare system in general 
and intensive care beds in particular have meant that patients 
with other acute illnesses and preventative health services 
have in some settings been de-prioritised [49]. Hospital 
capacity has also been used as an explicit metric by which 
to trigger other non-pharmaceutical interventions that have 
large effects on society and the economy. Sandmann and 
colleagues have explored several techniques for estimating 
the value of foregone bed-days in a scarcity setting [50], 
which could be incorporated into an economic evaluation 
of COVID-19 therapies that affect time in critical care or 
the hospital generally. The inclusion of both health sector 
and societal perspectives is recommended in evaluations of 
any pandemic treatments, whether vaccine or therapeutic.
3  Willingness‑To‑Pay/Cost‑Effectiveness 
Thresholds
In addition to the consideration of expanding the scope 
of economic evaluations for COVID-19 therapeutics with 
these elements of value, the appropriate cost-effectiveness 
threshold to apply has also been called into question. In the 
Institute for Clinical and Economic Review’s remdesivir 
assessment in 2020, the cost-effectiveness threshold was set 
at $50,000 per QALY in a departure from the organisation’s 
standard $100,000–$150,000 per QALY range, with the rea-
soning that thresholds should be reduced during pandemics 
with a sizable patient population uptake [16]. It is also pos-
sible to argue that inclusion of added value elements when 
valuing therapeutics should reduce the cost-effectiveness 
threshold further, at least from the healthcare sector per-
spective, as the additional elements of value take into con-
sideration non-health benefits. It could be argued that part of 
the payment for a fuller capture of value should be borne by 
sectors other than healthcare, and the threshold used to set 
a price for the healthcare sector should therefore be lower.
However, a higher threshold may be justified given the 
urgent need to restore functioning economies. Effective ther-
apies may not only have direct health benefits for the patient, 
but also have non-health effects around productivity and 
the opening of society by relieving pressure on the health-
care system. There may even be a case for the suspension, 
or abbreviation, of formal health technology assessment 
approaches during the pandemic in lieu of implicit judge-
ments, and to conduct value assessments at a later point. 
Therapeutics that treat human immunodeficiency virus, for 
example, have only in the past year been selected for a full 
technology appraisal by the National Institute for Health 
and Care Excellence in the UK, resulting from the 2019 
Voluntary Pricing and Access Scheme [51]. The National 
Institute for Health and Care Excellence has also issued 
rapid guidelines over the course of the pandemic specifi-
cally recommending the use of such therapeutics as tocili-
zumab without a formal technology appraisal [52, 53]. Sev-
eral other countries are also conducting abbreviated forms 
of their standard appraisals, sometimes foregoing economic 
analyses altogether. This can be seen in such examples as 
the modified approach used to develop COVID-19 therapy 
evidence reviews in Canada [54], or in Australia through the 
formation of a new taskforce dedicated to evaluating evi-
dence for COVID-19 clinical care. In countries where health 
technology assessments and economic evaluations are not as 
well established, such as India and other LMICs, it is even 
more likely that there has not been any explicit considera-
tion of a cost-effectiveness threshold or willingness to pay 
specifically for COVID-19.
It is important to remember, however, that even during, 
or perhaps especially during pandemic times, healthcare 
budgets are finite. Considering a higher cost-effectiveness 
threshold, or indeed suspending health technology assess-
ment altogether for a set period of time, which essentially 
signals an unlimited cost-effectiveness threshold, will need 
to balance the opportunity costs of such a suspension. Clax-
ton et al. have described methods for quantifying oppor-
tunity costs of investing in new technologies in the UK 
National Health Service and incorporating those costs in 
the National Institute for Health and Care Excellence cost-
effectiveness thresholds [55]. Incorporation of such oppor-
tunity costs would undoubtedly lead to a lower threshold 
given the impact on the ability of the healthcare system to 
offer services for other acute illnesses and preventive health 
services by funding COVID-19-specific therapies. These 
considerations may be particularly acute in LMICs, where 
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the trade-off between COVID-19-specific interventions and 
existing preventative health measures is likely to have a 
larger impact [56, 57]. There may also have to be considera-
tion of other COVID-19-specific, but non-therapeutic health 
measures, such as vaccines and screening programs. These 
are complicated not only by the estimation of opportunity 
costs, but also by the interactions between these efforts. A 
public health strategy including multiple measures may have 
different outcomes and value associated with it compared to 
individual strategies considered separately.
The consequences of altering the cost-effectiveness 
threshold should also be considered. Depending on the rea-
soning behind the alteration, this can send different signals 
to manufacturers about what innovations are desirable. Dedi-
cating resources to vaccines at the expense of therapeutics 
may disincentivize innovation for future treatments, which 
has implications for future pandemics where vaccines may 
not be developed with as much speed as has been the case 
for COVID-19, leading to more dependence on effective 
therapeutics.
When making decisions around the adoption of new tech-
nologies and the appropriate price, decision makers should 
be aware of these arguments, as well as the implications 
of altering an existing threshold specifically in response to 
a pandemic. In particular, there should also be awareness 
of the implications for post-pandemic and non-COVID19 
diseases in the future to maintain a sustainable healthcare 
system. Indeed, such implications further complicate the 
policy environment and could hamper the implementation 
of any health strategies that are considered a good use of 
resources. It requires a multi-stakeholder discussion, across 
several sectors, of whose resources we are trying to judi-
ciously allocate.
4  Conclusions
Economic evaluation principles remain unchanged within 
the context of COVID-19. However, given significant mor-
bidity and mortality, in addition to the widespread economic 
and public health impact of the COVID-19 pandemic, any 
treatment developed should be evaluated with a view toward 
the broader benefits of restoring economic and social activ-
ity; although quantifying some of these value elements, 
especially as the knowledge base evolves rapidly, is difficult. 
From a pragmatic perspective, the traditional health sector 
valuation of therapeutics should remain as a reference case. 
Modelling strategies allow us to evaluate both the traditional 
and potential larger societal value of COVID-19 therapeu-
tics. In the future, as the pandemic evolves into different 
stages, the elements of value discussed above may also 
shift in their relative importance. Where strong evidence 
of a therapeutic’s effect on the wider pandemic situation 
exists, the appropriate additional elements of value could 
be incorporated in a scenario analysis to highlight potential 
therapeutic value and to present a full picture to decision 
makers. As the external environment is evolving rapidly, it 
is important to remain reactive to the potential non-health 
benefits of an intervention, but also to retain a core reference 
case for comparison.
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